- Home
- Our Services
- Medical Device & IVD
- FDA 510(K)
Our Services
FDA 510(k) Consulting for Medical Devices & IVDs
A FDA 510(k) is a premarket notification submitted to the U.S. Food and Drug Administration (FDA) to demonstrate that a new medical device is substantially equivalent to a legally marketed predicate device already on the U.S. market. Most Class II medical devices — including in vitro diagnostics (IVDs), combination products, and Software as a Medical Device (SaMD) — require 510(k) clearance before they can be sold in the United States. The FDA does not “approve” a 510(k) device; it issues a clearance letter confirming substantial equivalence. The process typically takes 4 to 9 months, though a well-prepared submission reviewed by an expert consultant can significantly reduce deficiency cycles. Traccglobal is a global regulatory consultancy with a specialized FDA 510(k) consulting practice serving medical device manufacturers worldwide. Our 510(k) preparation and submission service covers the full cycle — from predicate selection and gap analysis to FDA correspondence and clearance — with a 97% first-cycle clearance rate.
What Is a 510(k) Submission? (And Why Most Companies Get It Wrong)
If you manufacture a Class II medical device — or a Class I device with special controls — and you want to sell it in the United States, you almost certainly need to file a 510(k) with the FDA’s Center for Devices and Radiological Health (CDRH).
Here is the core idea in plain language:
The FDA clears your device when it can find a predicate — an already-cleared device that shares the same intended use and substantially equivalent technological characteristics. If no predicate exists, you may need a De Novo classification request instead of a 510(k). Choosing the wrong pathway wastes months and thousands of dollars.
Where companies go wrong:
- Selecting the wrong predicate device (or multiple weak predicates)
- Submitting incomplete performance testing data
- Filing without understanding the FDA’s Special Controls for their product code
- Ignoring the FDA’s own guidance documents specific to their device type
- Treating eSTAR (Electronic Submission Template and Resource) as an afterthought
Traccglobal’s FDA 510(k) consultants have cleared devices across more than 60 FDA product codes. Before we write a single document, we build the regulatory strategy — because getting the strategy right is what separates a 90-day clearance from a 12-month back-and-forth.
Which Devices Require FDA 510(k) Clearance in 2026?
Not every device needs a 510(k) — but most do. Here is a clear breakdown:
Requires 510(k):
- Most Class II medical devices
- Class I devices with special controls (exempt status revoked)
- Devices introducing a new intended use to an existing cleared device
- Modified devices where the change may significantly affect safety or effectiveness
- Software as a Medical Device (SaMD) under Class II
- In Vitro Diagnostics (IVDs) — most moderate and high-complexity tests
- Combination products where the device constituent part is Class II
Does NOT require 510(k):
- Class I exempt devices (most low-risk, simple devices)
- Devices cleared under a previous 510(k) with no significant change
- Class III devices requiring PMA (Premarket Approval)
- Devices qualifying for the De Novo pathway (novel, low-to-moderate risk with no valid predicate)
Not sure which pathway applies to your device? Traccglobal’s regulatory team performs a free device classification and pathway determination as the first step of every engagement. This alone saves our clients an average of 3 months of misdirected preparation work.
Traccglobal's FDA 510(k) Consulting Process — Step by Step
Our process is built around one goal: your clearance letter, with zero unnecessary FDA cycles.
Step 1 — Regulatory Strategy & Predicate Selection
This is where most submissions are won or lost — before a single document is written.
Traccglobal reviews your device’s intended use, technological characteristics, and design to determine the FDA product code, regulation number, and applicable guidance documents. We then search the FDA 510(k) database to identify the strongest available predicate device — one that supports substantial equivalence on both intended use AND technological characteristics.
For IVDs and SaMD, we also assess whether a Safety and Performance Based Pathway (SPBP) is applicable, which can simplify the submission for devices in certain product categories.
What you get: A written regulatory strategy document, confirmed product code, recommended predicate(s), and a list of required tests and documents.
Step 2 — Gap Analysis & Documentation Review
Before we start building your 510(k), we review everything you already have.
Traccglobal conducts a formal Gap Analysis — a structured comparison of your existing technical documentation against the requirements for your specific product code. We identify every missing test, every incomplete document, and every labeling issue before you submit, not after the FDA asks.
Common gaps we find:
- Biocompatibility test reports not aligned with ISO 10993
- Electrical safety testing not referenced to current standards (IEC 60601-1 Edition 3.1 or 4th Edition)
- Performance data presented without statistical equivalence methodology
- Instructions for Use (IFU) not meeting FDA labeling requirements
- Software documentation (SaMD) not aligned with FDA’s 2023 Predetermined Change Control guidance
What you get: A detailed gap analysis report with a clear remediation checklist and estimated timeline to submission-readiness.
Step 3 — 510(k) Document Preparation
With the strategy confirmed and gaps closed, Traccglobal prepares your complete 510(k) submission package using the FDA’s eSTAR format (Electronic Submission Template and Resource) — which the FDA strongly recommends and which, in our experience, results in faster acceptance reviews.
The submission includes:
- Substantial equivalence comparison (side-by-side technical comparison with predicate)
- Device description with engineering drawings and design specifications
- Proposed labeling and Instructions for Use
- Performance testing summaries and full test reports
- Biocompatibility evaluation report (ISO 10993 series)
- Electrical safety and EMC test reports (where applicable)
- Software documentation package (IEC 62304, IEC 62366 for SaMD)
- Sterilization validation data (for sterile devices)
- Shelf life and packaging validation (ASTM F2475 / ISO 11607)
- Clinical/performance data (where required)
- Risk analysis summary (aligned with ISO 14971)
Every section is reviewed by a senior FDA regulatory consultant before submission. You review and approve the final package before we file.
What you get: A complete, submission-ready 510(k) dossier.
Step 4 — Submission & FDA Correspondence
Traccglobal submits your 510(k) electronically to CDRH via CDRH eSubmitter or the FDA Electronic Submissions Gateway (ESG). We serve as the Official Correspondent on your submission — meaning all FDA communications come directly to us for immediate, expert handling.
The FDA review process has three phases:
- Acceptance Review (15 days): FDA confirms the submission is complete enough to review
- Substantive Review (75 days): FDA reviewer assesses substantial equivalence in detail
- Interactive Review: FDA reviewer may engage directly with Traccglobal to resolve specific questions before issuing a decision
Traccglobal responds to all Additional Information (AI) requests within the fastest possible turnaround — typically 5 to 10 business days for standard requests. Speed here directly controls your total clearance timeline.
What you get: Real-time updates on your FDA submission status and expert handling of all FDA correspondence.
Step 5 — 510(k) Clearance & Post-Market Setup
When FDA issues your 510(k) clearance letter, Traccglobal confirms your device listing, establishment registration, and labeling compliance for launch-readiness.
We also advise on:
- Post-market surveillance obligations (MDR — Medical Device Reporting)
- 510(k) change management (when modifications require a new 510(k))
- FDA Quality System Regulation (21 CFR Part 820 / QSR) compliance for U.S. sales
Real Case Studies — How Traccglobal Got Our Clients FDA 510(k) Cleared
These case studies reflect real regulatory outcomes. Client names kept confidential per standard consulting practice.
Case Study 1: Cardiac Monitoring SaMD — 510(k) Cleared in 112 Days
Client: A mid-sized medical technology company from Germany developing an AI-powered ECG analysis software intended for cardiac arrhythmia detection.
Challenge: The client had previously received an FDA “Not Substantially Equivalent” (NSE) decision from a self-prepared submission. Their primary issue was predicate device selection — they had chosen a hardware-based monitor as the predicate for a pure software device, which FDA rejected on technological characteristics.
Traccglobal’s approach: We identified two cleared SaMD predicates with matching intended use and comparable algorithm-based outputs. We restructured the entire substantial equivalence argument, updated the software documentation to align with FDA’s 2023 AI/ML guidance, and addressed the previous NSE in a clear, point-by-point response in the new submission.
Result: 510(k) cleared in 112 days from submission — with zero Additional Information (AI) requests from FDA. Client launched in the U.S. market within 6 months.
Case Study 2: IVD Point-of-Care Glucose Monitor — 510(k) Clearance for OTC Use
Client: An Indian diagnostics manufacturer seeking U.S. FDA 510(k) clearance for an over-the-counter (OTC) blood glucose monitoring system.
Challenge: OTC glucose monitors are reviewed under FDA product code KZH and require clinical accuracy data per ISO 15197:2013 with specific FDA-mandated user study requirements for OTC labeling. The client’s existing ISO 15197 data was generated for professional use — not OTC — and did not include the lay-user study FDA requires.
Traccglobal’s approach: We designed a compliant OTC user study protocol, coordinated testing with a U.S.-based clinical study site, and integrated the OTC-specific accuracy data into a redesigned 510(k) dossier. The labeling was completely rewritten for U.S. consumers per FDA OTC labeling requirements.
Result: 510(k) cleared in 7 months. Client’s device is now listed on the FDA 510(k) database and sold in major U.S. retail pharmacy chains.
Case Study 3: Class II Orthopedic Implant — 510(k) Clearance with Q-Submission Strategy
Client: A U.S.-based startup developing a novel fixation device for minimally invasive spinal surgery — Class II under product code OZO.
Challenge: The device incorporated a new polymer material not previously used in cleared predicates. The client was unsure whether the FDA would accept the novel material data or require clinical studies, which would add 2–3 years to their timeline.
Traccglobal’s approach: We filed a Q-Submission (Pre-Submission) to the FDA before preparing the full 510(k). The Q-Sub secured FDA’s written agreement on: (1) the predicate device selection, (2) the biocompatibility testing protocol for the novel polymer, and (3) the biomechanical testing methods required. This eliminated uncertainty before the client spent on testing.
Result: 510(k) cleared in 9 months. The Q-Sub strategy saved the client an estimated $400,000 in potentially unnecessary clinical study costs.
FDA 510(k) Timeline — What to Realistically Expect in 2026
One of the most common questions we get: “How long will my 510(k) take?”
| Phase | Typical Duration | What Affects This |
|---|---|---|
| Regulatory strategy & predicate selection | 1–2 weeks | Device complexity, product code clarity |
| Gap analysis | 1–2 weeks | How much testing/documentation you already have |
| Gap closure (testing, documentation) | 4–16 weeks | Missing tests — especially biocompatibility and clinical data |
| 510(k) document preparation | 3–6 weeks | Device complexity, number of predicates |
| FDA Acceptance Review | Up to 15 days | Completeness of submission |
| FDA Substantive Review | 60–90 days (FDA goal) | Device type, reviewer workload, quality of submission |
| Additional Information (AI) response cycles | 30–90 days additional | How many questions FDA raises |
| Total — best case (simple device, strong predicates) | 4–5 months | |
| Total — typical Class II device | 6–9 months | |
| Total — complex device with novel features | 9–14 months |
FDA 510(k) Cost — What Does It Actually Cost?
There are two separate cost components: Traccglobal’s consulting fees and FDA user fees.
FDA User Fees (2026)
For fiscal year 2026, the standard FDA 510(k) user fee is $24,495 USD for standard companies. Small businesses (gross receipts under $100M) qualify for a reduced fee of $6,124 USD. Start-ups and companies in their first year of U.S. device sales may qualify for a fee waiver.
Note: FDA user fees change each fiscal year. Traccglobal always confirms the current applicable fee before your submission.
Traccglobal Consulting Fees
Our fees vary based on device complexity, documentation already in hand, and scope of the engagement. We provide a fixed-fee quote after the initial regulatory assessment — no hourly billing surprises.
As a general range:
- Simple Class II device (strong predicates, complete testing): Starting from $8,000–$15,000 USD
- Standard Class II device (gap closure + full 510(k) preparation): $15,000–$35,000 USD
- Complex device (SaMD, IVD, novel features, Q-Sub required): $35,000–$75,000+ USD
Traccglobal’s fees are significantly lower than the typical US-based 510(k) consulting firm for equivalent scope — without any reduction in quality. Our regulatory team has direct experience with FDA CDRH review processes. Contact Traccglobal for a free scoping call and fixed-fee proposal.
Why Traccglobal for FDA 510(k) Consulting?
Medical device companies choose Traccglobal because we treat every 510(k) as if our own product’s clearance depends on it. Here is what that means in practice:
Regulatory depth, not just project management. Our team understands FDA’s review process at a technical level — not just the paperwork. We have worked with CDRH reviewers, understand how different product code divisions approach submissions, and write 510(k)s the way FDA reviewers want to read them.
Fixed fees. No surprises. You get a complete scope and fixed price upfront. No hourly billing. No surprise invoices when your 510(k) gets an AI request.
One dedicated consultant per project. Your engagement is handled by a senior FDA regulatory consultant — not passed off to a junior team. You get direct access, direct communication, and direct accountability.
Global reach, U.S. focus. Traccglobal serves medical device companies in 20+ countries seeking U.S. FDA clearance. Whether you are a startup in India, a mid-size manufacturer in Europe, or an established company in the U.S. looking for a stronger consulting partner — we bring the same level of FDA regulatory expertise to every client. Visit traccglobal.com to learn more about our full range of global regulatory services.
Proven results. 97% first-cycle clearance rate. 100+ 510(k)s prepared and submitted. Clearances across cardiology, diagnostics, orthopedics, neurology, SaMD, and IVD product categories.
Frequently Asked Questions (FAQ) — FDA 510(k) Consulting
Q1. What is a 510(k) and when do I need one?
A 510(k) is an FDA premarket notification demonstrating that your device is substantially equivalent to a legally marketed predicate device. You need one if your Class II medical device (or certain Class I devices with special controls) is intended for the U.S. market, or if you are making changes to a cleared device that may significantly affect safety or effectiveness.
Q2. How long does FDA 510(k) clearance take?
The FDA’s goal is to review standard 510(k)s within 90 days under MDUFA V. In practice, total clearance time (including preparation) is typically 6–9 months for most Class II devices. Well-prepared submissions by experienced consultants see fewer AI requests, which is the single biggest driver of delays.
Q3. What is "substantial equivalence" and how do I prove it?
Substantial equivalence means your device has (1) the same intended use as a predicate, and (2) either the same technological characteristics, or different technological characteristics that do not raise new safety/effectiveness questions and perform at least as well as the predicate. You prove it with a direct technical comparison, supported by performance testing data.
Q4. What is a predicate device and how do I choose one?
A predicate is a legally marketed device (cleared via 510(k), or marketed before May 28, 1976) that you claim substantial equivalence to. Choosing the right predicate is the single most critical decision in a 510(k). A weak or mismatched predicate is the #1 cause of Not Substantially Equivalent (NSE) decisions. Traccglobal conducts a thorough predicate search before any other work begins.
Q5. What is a Q-Submission and do I need one?
A Q-Submission (Pre-Submission) is a voluntary request to FDA CDRH for written feedback before you file your 510(k). It is strongly recommended for novel devices, devices with new materials, and any situation where you are uncertain about FDA’s testing expectations. Traccglobal routinely uses Q-Subs as a risk-reduction strategy — FDA’s written responses from a Q-Sub are binding and protect you from surprises during substantive review.
Q6. Can Traccglobal handle SaMD (Software as a Medical Device) 510(k)s?
Yes. Traccglobal has specific expertise in SaMD 510(k) submissions, including AI/ML-based software, diagnostic algorithms, and clinical decision support tools. We align all SaMD submissions with FDA’s 2023 AI/ML guidance, IEC 62304 (software lifecycle), and IEC 62366 (usability engineering).
Q7. What happens after 510(k) clearance?
After clearance, you must: complete your FDA establishment registration, list your device in the FDA device database, comply with Quality System Regulation (21 CFR Part 820), and fulfill post-market reporting obligations. Traccglobal advises on all post-clearance compliance requirements to ensure your U.S. market entry is legally complete.
Q8. Is 510(k) clearance valid permanently?
510(k) clearance does not expire as long as your device remains unchanged. However, significant modifications — to intended use, design, materials, or labeling — may require a new 510(k). Traccglobal provides change management reviews to assess whether a modification triggers a new submission requirement.
Q9. What is the De Novo pathway and when does it apply?
The De Novo pathway is for novel, low-to-moderate risk devices that have no valid 510(k) predicate. Instead of demonstrating substantial equivalence, you petition FDA to create a new device classification with specific special controls. De Novo is more resource-intensive than a 510(k) but, once granted, your device itself becomes an eligible predicate for future 510(k) submissions by others. Traccglobal handles De Novo requests as part of our FDA regulatory services.
Q10. How is Traccglobal different from other 510(k) consultants?
Traccglobal combines deep regulatory expertise with fixed, transparent pricing and a fully dedicated team — not a rotating cast of junior staff. We work across the full spectrum from pre-submission strategy through post-market compliance, and we have direct experience with FDA CDRH processes across 60+ product codes. Unlike large consulting firms that bill by the hour, Traccglobal gives you a fixed-fee proposal upfront. Our 97% first-cycle clearance rate speaks for itself.
Our Services
Let Us Know Your Requirements
Call Emergency
+918868886774
What Our Clients Says
Real feedback from our happy clients about our quality and service.
